Funding for this research was provided by:
Received: 23 November 2022
Accepted: 6 March 2023
First Online: 28 April 2023
: C.J.A.P. has an advisory role for Nordic Pharma. K.B. reports having an advisory role for Amgen. J.H.W.d.W. has an unrestricted grant from Medtronic. U.P.N. reports presentations or contribution to research for Roche, Astra Zeneca, Merck AG, Sanofi, Grünenthal, Johnson & Johnson and Astellas. This funding is not related to the current research. The remaining authors declare no potential conflicts of interest.